Triumph Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
Other funds holding PBE
Triumph Capital Management's PBE Position: Q3 2026 in Review
Triumph Capital Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2026 at 34 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.
Triumph Capital Management first reported a position in PBE in Q4 2025 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold PBE as of Q3 2026.
- Triumph Capital Management held 34 shares of Invesco Biotechnology & Genome ETF worth $3.31K as of Q3 2026.
- Triumph Capital Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2026.
- Invesco Biotechnology & Genome ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1517 holding.
- Triumph Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2025 and has held it in 4 quarters since.
- 122 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.
Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.